Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011.

Autor: O’Donnell, Peter H.¹ (AUTHOR) podonnel@bsd.uchicago.edu, Loriot, Yohann² (AUTHOR), Csoszi, Tibor³ (AUTHOR), Matsubara, Nobuaki⁴ (AUTHOR), Shin, Sang Joon⁵ (AUTHOR), Park, Se Hoon⁶ (AUTHOR), Atduev, Vagif⁷ (AUTHOR), Gumus, Mahmut⁸ (AUTHOR), Karaca, Saziye Burcak⁹ (AUTHOR), Grivas, Petros^10,11 (AUTHOR), Wit, Ronald¹² (AUTHOR), Castellano, Daniel E.¹³ (AUTHOR), Powles, Thomas¹⁴ (AUTHOR), Vuky, Jacqueline¹⁵ (AUTHOR), Zhao, Yujie¹⁶ (AUTHOR), O’Hara, Karen¹⁷ (AUTHOR), Okpara, Chinyere E.¹⁷ (AUTHOR), Franco, Sonia¹⁶ (AUTHOR), Homet Moreno, Blanca¹⁶ (AUTHOR), Żołnierek, Jakub¹⁸ (AUTHOR)

Publikováno v: Cancer (0008543X). Oct2024, p1. 11p. 4 Illustrations.

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011.

Autor: O'Donnell PH; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA., Loriot Y; Early Drug Development Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France., Csoszi T; Jász-Nagykun-Szolnok County Hospital, Szolnok, Hungary., Matsubara N; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Shin SJ; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Park SH; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Atduev V; Volga District Medical Center, Federal Medical-Biological Agency, Nizhny Novgorod, Russia., Gumus M; Department of Medical Oncology, Istanbul Medeniyet University, Istanbul, Turkey., Karaca SB; Ege University Faculty of Medicine, Tülay Aktas Oncology Hospital, Izmir, Turkey., Grivas P; Division of Hematology/Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Castellano DE; Department of Medical Oncology, Hospital Universitario 12 de Octubre, GUARD Consortium, Madrid, Spain., Powles T; Department of Genitourinary Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Vuky J; Department of Medicine/Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA., Zhao Y; Merck & Co, Inc, Rahway, New Jersey, USA., O'Hara K; Eisai, Ltd, Hatfield, UK., Okpara CE; Eisai, Ltd, Hatfield, UK., Franco S; Merck & Co, Inc, Rahway, New Jersey, USA., Homet Moreno B; Merck & Co, Inc, Rahway, New Jersey, USA., Żołnierek J; LUXMED Oncology, Warsaw, Poland., Siefker-Radtke AO; Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: Cancer [Cancer] 2024 Oct 28. Date of Electronic Publication: 2024 Oct 28.